YWYifan Wang

Yifan Wang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Yifan Wang has a total of 19 co-authors. Here are the top co-authors by number of shared publications:

  • Fengyun Wang

    Institute of Digestive Diseases, Xiyuan Hospital of China Academy of Chinese, Medical Sciences, China

    3 shared publications
  • Xudong Tang

    Institute of Digestive Diseases, Xiyuan Hospital of China Academy of Chinese Medical Sciences, Beijing, China

    3 shared publications
  • Jiaqi Zhang

    Institute of Digestive Diseases, Xiyuan Hospital of China Academy of Chinese Medical Sciences, Beijing, China

    2 shared publications
  • Jing Ma

    Institute of Digestive Diseases, Xiyuan Hospital of China Academy of Chinese Medical Sciences, Beijing, China

    2 shared publications
  • Jinke Huang

    Department of Gastroenterology, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine (Guangdong Provincial Hospital of Chinese Medicine), Guangzhou, China

    2 shared publications
  • Beihua Zhang

    Department of Gastroenterology, Xiyuan Hospital of China Academy of Chinese Medical Sciences, Beijing, 100091, China; Institute of Digestive Diseases, Xiyuan Hospital of China Academy of Chinese Medical Sciences, Beijing, 100091, China

    1 shared publication

Latest Publications

  • Open Access

    Modified Gegen Qinlian Decoction Ameliorates DSS‐Induced Colitis in Mice via the Modulation of NF‐ κ B and Nrf2/HO‐1 Pathways

    by Jinke Huang, Jiaqi Zhang, Zhihong Liu, Jing Ma, Yifan Wang, Fengyun Wang, Xudong Tang

    Background: This study aims to reveal the potential molecular mechanisms of modified Gegen Qinlian decoction (MGQD) in relieving ulcerative colitis (UC). Methods: C57BL/6J mice were used to establish experimental colitis via dextran sodium sulfate (DSS). Body weight, disease activity index (DAI), spleen weight, colon length, and histopathologic features were measured to evaluate the therapeutic effects of MGQD on mice with UC. The ELISA kits were employed to assess the concentrations of interleukin (IL)‐6, IL‐1β, tumor necrosis factor‐α (TNF‐α), glutathione (GSH), reactive oxygen species (ROS), and malondialdehyde (MDA). Western blot analyses were used to assess the levels of IκBα, p65, p‐IκBα, p‐p65, HO‐1, and Nrf2. Moreover, the protein levels of Nrf2 and p‐p65 were assessed by immunofluorescence. Results: Colitis‐related symptoms in mice were significantly alleviated by MGQD. Moreover, MGQD inhibited the levels of TNF‐α, IL‐1β, IL‐6, MDA, and ROS and increased the level of GSH in mice with UC. Mechanistically, MGQD prevented the activation of the NF‐κB pathway and concomitantly promoted the activation of the Nrf2/HO‐1 pathway. Conclusion: MGQD alleviated UC by suppressing inflammation and oxidative stress via the modulation of NF‐κB and Nrf2/HO‐1 pathways, suggesting that MGQD may be a candidate therapy for UC.


  • Modified Gegen Qinlian decoction ameliorated ulcerative colitis by attenuating inflammation and oxidative stress and enhancing intestinal barrier function in vivo and in vitro

    by Yifan Wang, Jiaqi Zhang, Beihua Zhang, Mengxiong Lu, Jing Ma, Zhihong Liu, Jinke Huang, Jinxin Ma, Xuefei Yang, Fengyun Wang, et al.


  • Open Access

    Scientific Evidence of Chinese Herbal Medicine (Gegen Qinlian Decoction) in the Treatment of Ulcerative Colitis

    by Jinke Huang, Jiaqi Zhang, Yifan Wang, Jing Ma, Xuefei Yang, Xiaoxue Guo, Mi Lv, Jinxin Ma, Yijun Zheng, Fengyun Wang, et al.

    Objectives. Gegen Qinlian decoction (GQD), a Chinese herbal compound, has been widely used in the treatment of ulcerative colitis (UC) in China. However, evidence from systematic reviews (SRs)/meta-analyses (MAs) of GQD in UC remains highly controversial. To collate, evaluate, and synthesize the current evidence, we carried out this study. Methods. SRs/MAs of GQD for UC were obtained from eight databases. Methodological Quality of Systematic Reviews 2 (AMSTAR-2) was utilized to appraise the methodological quality, Preferred Reporting Item for Systematic Reviews and Meta-Analyses (PRISMA) for reporting quality, and Grading of Recommendations Assessment, Development, and Evaluation (GRADE) for evidence quality. Results. Four eligible SRs/MAs were obtained. According to AMSTAR 2, all SRs/MAs were graded as critically low quality. According to PRISMA checklist, all SRs/MAs failed to report the information of protocol and registration. With GRADE, no outcome measure with high-quality evidence was found, and the evidence quality for outcome measures was in the moderate to critically low levels. Conclusions. GQD with conventional medicine (CM) seems to be more effective in UC than CM alone. This finding provides a new alternative strategy for the treatment of UC. However, owing to the limitations of the evidence provided by the included SRs/MAs, this conclusion must be treated with caution.